CorMedix outlines $300M-$320M revenue and $100M-$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration
Source: SeekingAlpha
2026-03-05 14:56:38 ET
More on CorMedix
- CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
- CorMedix Inc. (CRMD) Analyst/Investor Day Transcript
- CorMedix Inc. (CRMD) Analyst/Investor Day - Slideshow
- CorMedix nears an 11-month low after earnings miss
- CorMedix reports mixed Q4 results; reaffirms FY26 outlook
Read the full article on Seeking Alpha
For further details see:
CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration
CorMedix Inc.
NASDAQ: CRMD
CRMD Trading
-2.59% G/L:
$6.58 Last:
454,214 Volume:
$6.73 Open:
CRMD Latest News
March 05, 2026 07:30:00 am
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CRMD Stock Data
$605,887,756
76,346,585
2.82%
76
N/A
Biotechnology & Life Sciences
Healthcare
US
Berkeley Heights
